2-(2-甲基-1H-咪唑-1-基)-1-苯基乙酮 | 57432-71-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 2-(2-甲基-1H-咪唑-1-基)-1-苯基乙酮
• 英文名称: 2-(2-methyl-1H-imidazol-1-yl)-1-phenylethanone
• 英文别名: 1-benzoylmethyl-2-methylimidazole；2-(2-methylimidazol-1-yl)-1-phenylethanone
• CAS: 57432-71-0
• 化学式: C₁₂H₁₂N₂O
• 分子量: 200.24
• InChiKey: SKHPONDLDUHXLE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  34.9
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(2-甲基-1H-咪唑-1-基)-1-苯基乙酮 生成 2-bromo-2-(2-methylimidazol-1-yl)-1-phenylethanone
  参考文献：
  名称：

  FUJITA, TAKAYUKI;KITAZAWA, YOSHIKAZU;AKITA, TADASHI;TANI, ISAMU

  摘要：

  DOI：
• 作为产物：
  描述：

  2-溴苯乙酮 在 potassium carbonate 作用下， 以 丙酮 为溶剂， 反应 0.41h， 以48%的产率得到2-(2-甲基-1H-咪唑-1-基)-1-苯基乙酮
  参考文献：
  名称：

  WO2006/68594

  摘要：

  公开号：

文献信息

• Heterocyclic Mchr1 Antagonists And Their Use In Therapy
  申请人：Egner Bryan

  公开号：US20080306055A1

  公开（公告）日：2008-12-11

  Compounds of formula I depicted below, pharmaceutical compositions containing them, processes for preparing the compounds, and their use in the treatment of obesity, type II diabetes, metabolic syndrome, psychiatric disorders, cognitive disorders, memory disorders, schizophrenia, epilepsy and related conditions, neurological disorders such as dementia, multiple sclerosis, Parkinson's disease, Huntington's chorea and Alzheimer's disease, and pain related disorders. The compounds are melanin concentrating hormone receptor 1 (MCHr1) antagonists.

  以下为式I的化合物，含有它们的制药组合物，制备这些化合物的方法，以及它们在治疗肥胖症、2型糖尿病、代谢综合征、精神障碍、认知障碍、记忆障碍、精神分裂症、癫痫及相关疾病、神经疾病如痴呆、多发性硬化症、帕金森病、亨廷顿舞蹈症和阿尔茨海默病以及与疼痛有关的疾病中的使用。这些化合物是黑色素浓集激素受体1（MCHr1）拮抗剂。
• Cobalt-catalyzed tandem one-pot synthesis of polysubstituted imidazo[1,5-<i>a</i>]pyridines and imidazo[1,5-<i>a</i>]isoquinolines
  作者：Neha Meena、Shiv Dhiman、Krishnan Rangan、Anil Kumar

  DOI：10.1039/d2ob00526c

  日期：——

  An efficient cobalt-catalyzed tandem one-pot method has been developed for the synthesis of polysubstituted imidazo[1,5-a]-N-heteroaromatics. The method involves Knoevenagel condensation followed by cobalt-catalyzed direct alkenylation to give the desired polysubstituted imidazo[1,5-a]pyridines and imidazo[1,5-a]isoquinolines in a one-pot manner. This method exhibits a broad substrate scope, provides

  开发了一种高效的钴催化串联一锅法合成多取代的咪唑并[1,5 - a ]-N-杂芳烃。该方法涉及 Knoevenagel 缩合，然后是钴催化的直接烯基化，以一锅方式得到所需的多取代咪唑并[1,5- a ]吡啶和咪唑并[1,5 - a ]异喹啉。这种方法表现出广泛的底物范围，提供中等至良好（39-74%）的产量，并且可以放大到克级。
• Novel inhibitors of nitric oxide synthase with antioxidant properties
  作者：Loredana Salerno、Maria N. Modica、Giuseppe Romeo、Valeria Pittalà、Maria A. Siracusa、Maria E. Amato、Rosaria Acquaviva、Claudia Di Giacomo、Valeria Sorrenti

  DOI：10.1016/j.ejmech.2012.01.002

  日期：2012.3

  We previously described a series of imidazole-based inhibitors substituted at N-1 with an arylethanone chain as interesting inhibitors of neuronal nitric oxide synthase (nNOS), endowed with good selectivity vs endothelial nitric oxide synthase (eNOS). As a follow up of these studies, several analogs characterized by the presence of substituted imidazoles or other mono or bicyclic nitrogen-containing heterocycles instead of simple imidazole were synthesized, and their biological evaluation as in vitro inhibitors of both nNOS and eNOS is described herein. Most of these compounds showed improved nNOS and eNOS inhibitory activity with respect to reference inhibitors. Selected compounds were also tested to analyze their antioxidant properties. Some of them displayed good capacity to scavenge free radicals and ability to reduce lipid peroxidation. (C) 2012 Elsevier Masson SAS. All rights reserved.
• FUJITA, TAKAYUKI;KITAZAWA, YOSHIKAZU;AKITA, TADASHI;TANI, ISAMU
  作者：FUJITA, TAKAYUKI、KITAZAWA, YOSHIKAZU、AKITA, TADASHI、TANI, ISAMU

  DOI：——

  日期：——
• HETEROCYCLIC MCHr1 ANTAGONISTS AND THEIR USE IN THERAPY
  申请人：AstraZeneca AB

  公开号：EP1831194A1

  公开（公告）日：2007-09-12